Latest From the
world of Reformulary

New study underscores importance of medical cannabis rating system

Reformulary 2019 Year in Review

Cannabis Standard Insights, Issue #2 published by Reformulary Group

CIX Canadian Innovation Exchange announced Reformulary Group as a CIX TOP 20 Early innovative Canad...

Letter to the editor: Pharmacare – not all Canadians, not all drugs

The challenges with medical cannabis in the workplace

Reformulary Group creates online community platform for info on medical cannabis

Reformulary Group launches medical cannabis formulary

Reformulary 2018 Year in Review

Canada’s first evidence-based medical cannabis formulary launches

The Reformulary, now available through Great-West Life

Opioid Prescribing in Canada and its Potential Contribution to the Opioid Crisis.